Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressiv
资讯
2026-05-15
Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 Planned
CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceu...